Research

A new systematic review analyzing drug pricing policies in sub-Saharan Africa.

Webinar 5

This study demonstrates the real-world effectiveness of COVID-19 vaccines.

The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.

In this Perspective, researchers use a network simulation model to illustrate five different vaccination strategies for coronavirus disease 2019 (COVID-19).

Accelerated COVID-19 Vaccine Development Status and Efforts to Address Manufacturing Challenges

Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma

A subset of generic prescription drugs, complex generics are copies of non-biologic medicines that have a complex molecular base, route of delivery, formulation, or dosage form.

Usually in January, every year, a large number of pharmaceutical companies update product prices - a trend that often receives public attention in the media, for better or for worse.

Cost-sharing schemes should be evaluated based on their overall impact on welfare, which can be very different from the price elasticity of demand.

Current drug assessments place an unfair burden on rare disease drugs in comparison to non-rare disease drugs.

This working paper describes CBO's simulation model of drug price negotiations under the Elijah E. Cummings Lower Drug Costs Now Act in detail, including its data sources and parameter values, and the sensitivity of the results.

Half of all Part D-covered drugs (50%, or 1,646 drugs) had list price increases that exceeded the rate of inflation between July 2018 and July 2019.

Supplementary information.

Which nation is the most attractive destination for prescription drug launches?